AZNCF News and Press, AstraZeneca Plc From 05/04/21

Healthcare offers essential services that people can't go without, recession or not. The Tekla funds can offer potential in any one of their funds for healthcare exposure. Today we explore the differences and the similarities of the funds. For further details see: Tekla ...

When the market is in a phase of rich valuation, it is tempting to broadly identify the market for these stocks as “overvalued”. Making the distinction between stocks deserving high valuations and those that are overvalued is key, particularly in the current market. ...

AstraZeneca PLC (AZN) Q1 2021 Earnings Conference Call April 30, 2021, 06:45 AM ET Company Participants Pascal Soriot - ED and CEO Dave Fredrickson - EVP, Oncology Business Unit Ruud Dobber - EVP, Biopharmaceuticals Business Unit Marc Dunoyer - ED and CFO Mene Pangalos - EVP, Biopharmaceutica...

The following slide deck was published by AstraZeneca PLC in conjunction with their 2021 Q1 earnings call. For further details see: AstraZeneca PLC 2021 Q1 - Results - Earnings Call Presentation

Fisher’s 13F portfolio value increased from ~$133.5B to ~$142B in Q1 2021. They increased Walt Disney and Eli Lilly while trimming Taiwan Semi, JD.com, and Pinduoduo. Fisher has a number of small positions in several ETFs/ETNs. For further details see: Tracking Ke...

Despite 50% gains over the last year, the S&P 500 and stocks, in general, likely have substantially more upside. Ultra-easy Fed policy remains the primary catalyst for higher asset prices. Yet, there are numerous secondary catalysts that are capable of propelling stock prices ...

Bristol-Myers Squibb is currently enjoying a diversified asset portfolio whose sales are expected to keep growing going forward. The stock's valuation is hard to justify even when accounting for patent expirations potentially hurting revenues post-2025. The company is a free cash ...

I received the first dose of my COVID-19 vaccine a couple of weeks ago. It was an "interesting" experience, but I do not regret receiving the shot. I remain bullish on the vaccine industry. Some of my favorite names, and why I like these companies. For further details se...

Merger activity increased last week with six new deals announced. $50 billion worth of deals announced in a single week. Thermo Fisher Scientific to acquire PPD Inc. For further details see: Merger Arbitrage Mondays - Microsoft's Acquisition Of Nuance Offers A 5% Spread ...

AstraZeneca is a hyper-growth blue chip that expects a return to dividend growth in 2022. With one of the most promising drug pipelines in the industry, it could expand far faster than what it's enjoyed historically. In a world where hyper growth often trades at dangerous valuatio...